As the American Psychiatric Association prepares to release the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders, or DSM-5, a long brewing controversy over the work has erupted into the mainstream. We spoke to Allen Frances, professor emeritus at Duke University and chairman of the DSM IV task force, about his criticism of the new manual, the damage he fears it will cause, and what he calls “the medicalization of normal.” Read More
Innovation
- Obama Administration Offers $1 Billion for Healthcare Innovation
HHS awards designed to transform delivery and payment systems. Read More
Deals
- Pharma to Support Early-Stage Biotechs
Roche and Bayer team with QB3 while Atlas Ventures rounds up Amgen and Novartis. Read More
Stem Cells
- Scientists Report Human Stem Cell Cloning Success
Caffeine and healthy cytoplasm promote growth following nuclear transfer. Read More
Court Rulings
- Supreme Court Rules Unanimously in Favor of Monsanto
Judges find Indiana farmer violated company’s patent when he reproduced its biotech seed. Read More
Dealmaking
- AbbVie Options Alvine Celiac Drug for $70 Million
Collaboration could broaden pharma’s autoimmune pipeline. Read More
Business Models
- Elan Buys Stake in Theravance Royalties on Drugs
Deal gives Irish company a 21 percent stake in future payments associated with four respiratory programs. Read More
Medical Devices
- Carmat to Implant its Artificial Heart in Human Patients
First use of bioprosthetic will take place in four countries. Read More
Obesity
- Lack of Intestinal Bacteria Linked to Obesity
Mice fed a mucus-loving microbe lost weight. Read More
Business Strategy
- Astellas to Consolidate R&D
Japanese pharma plans to outsource some functions while bringing others closer to its headquarters. Read More
Trials and Tribulations
- Drug Recalls Up Over Last Year
The weekly round-up of failed trials, missed targets, and other business mishaps. Read More
- The Burrill Report (May 20, 2013): Saving Normal
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
Learn about the essential role remote monitoring will be play in controlling health care costs for Europe's aging population.
Read now
May 2013
Download a free copy of the May 2013 issue of The Burrill Report. Focus on: Q1 Review
Click here to download
Ron Pollack, executive director of the consumer health organization Families USA, disccusses the government's release of hospital pricing data, what it tells us, and why transparency is critical to addressing the high cost of healthcare.
Capital Scorecard
Filed IPOs
Completed IPOs
PDUFA Dates
Drug Approvals
Burrill Indices
Biggest Movers
Three life sciences companies completed initial public offerings during the second week of May, as the Dow Jones Industrial Average broke the 15,000 mark and the S&P 500 climbed to new highs.
.jpg)
.gif)
.png){kind=small} |
 |